Current Insights and Future Perspectives into Signaling Pathways and Mechanisms of Drug Resistance in Cancer

Dear Colleagues,

Cancer is a common disease responsible for a significant proportion of human mortality, with there being over 200 types of cancers. The high death rate in cancer patients is due to delayed diagnosis and the lack of standard and effective treatment. Surgery is less effective in treating metastatic cancer because removing all of the cancer cells that have spread to other organs is difficult. The severity of cancer as a health problem is evidenced by statistical analysis of cancer incidence and mortality. Chemotherapy is the standard therapy for treating metastasized cancer, but drug resistance to chemotherapy is a major hurdle in achieving satisfactory results and can lead to treatment failure. There are two types of resistance—inherent and acquired—which are caused by various mechanisms such as drug target mutations, increased detoxification, increased cell tolerance to apoptosis, and increased DNA damage repair. Intracellular signaling pathways are important for the normal functioning of cells and can be activated by various factors. Abnormal activation of these pathways can lead to drug resistance in cancer treatment. Targeting these pathways can help overcome drug resistance. This Special Issue, “Current Insights and Future Perspectives into Signaling Pathways and Mechanisms of Drug Resistance in Cancer”, focuses on the roles of these pathways in drug resistance to anticancer agents.

In this Special Issue, both original research articles and reviews are welcome. Submissions can cover any relevant topic, including the current and future perspectives of targeting EGFR, PI3K/Akt/mTOR, Wnt, β-Catenin, TGF-β, and Notch signaling pathways; redox-related pathways; and the epigenetic change-mediated reprogramming of cell signaling to overcome drug resistance.

Dr. Ranjana Kanchan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer
• drug resistance
• drug transporters
• cell signaling
• metabolic reprogramming
• miRNA
• nonapoptotic and apoptotic cell death